Compare Ulta Beauty Inc (ULTA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ulta Beauty Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Ulta Beauty Inc trades at $562.39 (market cap $23.32B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.5× Ulta Beauty Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ulta Beauty Inc for 92 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| ULTA | VRTX | |
|---|---|---|
Market Cap | $23.32B | $128.16B |
Volume | 321,683 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $706.82 | $557.96 |
52-Week Low | $450.75 | $407.37 |
Typical Hold Time | 92 Days | 120 Days |
Enterprise Value | $25.63B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ULTA trades at $564.21, up 3.09% today, with a bullish technical outlook and strong analyst support. The stock has shown robust earnings beats in recent quarters, with Q1 and Q2 2026 exceeding expectations, and the company raised its 2026 guidance. Revenue growth is steady, though net margins have softened slightly from 12.17% in 2023 to 10.63% in 2025. Valuation ratios like a P/E of 19.86 and P/S of 1.86 appear reasonable relative to profitability metrics such as a 46.12% ROE.
The investment case hinges on execution of raised guidance and e-commerce momentum, but risks include margin pressure and flat store traffic. With a consensus price target of $624.93 implying ~11% upside and no sell ratings from analysts, the stock presents a growth opportunity tempered by near-term consumer and competitive challenges.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
